Remove Consulting Remove Events Remove Physicals Remove Screening
article thumbnail

Didn’t Match into Residency.What are Some of my Options?

Aspiring Minority Doctor

Also, when you do re-apply for a residency position, you will be considered a graduating medical student senior which is useful for those residency programs that automatically screen out graduates. The drawback is having to travel all around a city and you may have to enter homes that may be unsanitary or in unsafe areas.

GP 52
article thumbnail

Hearing Loss in Geriatrics and Palliative Care: A Podcast with Nick Reed and Meg Wallhagen

GeriPal

Screening for addressing hearing loss should be an integral part of what we do in geriatrics and palliative care, but it often is either a passing thought or completely ignored. How to screen for hearing loss. And one of the parts of that was actually doing physicals for the students and putting them in job placements.

IT 102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Less than Meets the Eye: LDT Small Entity Compliance Guide Adds Little Insight

FDA Law

Timeliness is critical not only for developing appropriate corrective actions but also for evaluating and, when necessary, submitting reportable events to FDA as discussed below. establish and maintain adverse event files.” [9] report certain device malfunctions, and.

article thumbnail

EMS Intervention to Reduce Falls: Carmen Quatman and Katie Quatman-Yates

GeriPal

The insight started when Carmen, an orthopedic surgeon-researcher, and Katie, a physical therapist- researcher participated in ride-alongs with EMS providers to patient’s homes. And one person even called the system 75 times and that was just a light-bulb event for me. laughter] Carmen, welcome to the GeriPal podcast!

Community 114
article thumbnail

Better Late Than Never – Unpacking FDA’s Highly Anticipated (and Long Overdue) Draft Guidance on Diversity Action Plans

FDA Law

This could be based on differential pharmacokinetics (“PK”) or pharmacodynamics (“PD”), possible differences in susceptibility to specific adverse events of concern, or due to differential presentation of the disease or condition. FDA encourages sponsors to consult patients and healthcare providers to assist in developing such strategies.

Clinic 59